John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

ESMO congrès (European Society For Medical Oncology) 2019: what is new in GI Oncology? Volume 26, supplement 6, Décembre 2019

  • [1] Tie J., Wang Y., Tomasetti C. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346-392.
  • [2] Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019 May 9. doi : 10.1001/jamaoncol.2019.0528.[Epub ahead of print].
  • [3] Taieb J, Taly V, Vernerey D, et al. Analysis of circulating tumor DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration. A GERCOR-PRODIGE study. ESMO meeting 2019, Abstract LBA 30.
  • [4] Grothey A., Sobrero A.F., Shields A.F. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177-1188.
  • [5] Tarazona Llavero N, Gimeno-Valiente F, Gambardella V, et al. Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype. ESMO meeting 2019, Abstract 5220.
  • [6] Seymour MT, Morton D. FOxTROT: An international randomised controlled trial in 1052 patients evaluating neoadjuvant chemotherapy for colon cancer. ASCO meeting 2019, Abstract 3504.
  • [7] Morton D. FOxTROT : An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the FOxTROT Collaborative Group. ESMO meeting 2019, Abstract 523O.
  • [8] Kopetz S, Grothey A, Van Cutsem E, et al. BEACON CRC: A randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. ESMO GI meeting 2019, Abstract LBA 006.
  • [9] Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus Cetuximab With or Without Binimetinib for BRAF V600E–Mutant Metastatic Colorectal Cancer: Expanded results from a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. ESMO meeting 2019, Abstract LBA 32.
  • [10] Le D.T., Uram J.N., Wang H. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.
  • [11] Schmoll H.J., Wittig B., Arnold D. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: A randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014;140:1615-1624.
  • [12] Cunningham D, Salazar R, Sobrero A, et al. Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment : Results from the randomized phase 3 IMPALA trial. ESMO meeting 2019, Abstract LBA 33.
  • [13] Xu J, Liu T, Tang W, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A single center randomized control trial. ESMO meeting 2019, Abstract LBA 31.
  • [14] Cremolini C, Antoniotti C, Lonardi S, et al. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC. ASCO meeting 2019, Abstract 3508.
  • [15] Meric-Bernstam F., Hurwitz H., Raghav K.P.S. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518-530.
  • [16] Strickler JH, Zemla T, Ou FS, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC) : Initial results from the MOUNTAINEER trial. ESMO meeting 2019 Abstract PD527.
  • [17] Sartore-Bianchi A, Martino C, Lonardi S, et al. Phase II Study of Pertuzumab and Trastuzumab-emtansine (T-DM1) in Patients with HER2-positive Metastatic Colorectal Cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) Trial. ESMO meeting 2019, Abstract LBA 35.
  • [18] Tabernero J, Van Cutsem E, Bang YJ, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma : The phase III KEYNOTE-062 study. ASCO meeting 2019, Abstract LBA 4007.
  • [19] Shitara K, Van Cutsem E, Bang YJ, et al. Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062 ESMO meeting 2019, Abstract LBA 44.
  • [20] Kudo T., Hamamoto Y., Kato K. Nivolumab treatment for oesophageal squamous-cell carcinoma: An open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631-639.
  • [21] Cho BC, Kato K, Takahashi M, et al. Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 ATTRACTION-3 Study. ESMO meeting 2019, Abstract 2389.
  • [22] Shah MA, Adenis A, Enzinger PC, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. ASCO meeting 2019, Abstract 4010.
  • [23] Li J., Qin S., Xu J. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448-1454.
  • [24] Kang YK, Kang WK, Di Bartolomeo M, et al. Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens. ESMO meeting 2019, Abstract LBA 43.
  • [25] Von Hoff D.D., Ervin T., Arena F.P. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703.
  • [26] Hammel P, Lacy J, Portales F, et al. Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). ASCO meeting 2018, Abstract 204.
  • [27] Cascinu S, Berardi R, Bianco R, et al. Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial. ESMO meeting 2019, Abstract PD673.
  • [28] Kunzmann V, Algül H, Goekkurt E, et al. Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP) : Final results of a multicenter randomised phase II AIO trial ESMO meeting 2019, Abstract 671O.
  • [29] Lowery MA, Burris HA, 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: A phase 1 study. Lancet Gastroenterol Hepatol 2019 ; 4 : 711-720.
  • [30] Abou-Alfa GK, Macarulla Mercade T, Javle M, et al. ClarIDHy : A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. ESMO meeting 2019, Abstract LBA 10.
  • [31] Yau T, Park JW, Finn RS, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). ESMO meeting 2019, Abstract LBA 38.
  • [32] Finn RS, Ryoo BY, Merle P, et al. Results of KEYNOTE-240: Phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). ASCO meeting 2019, Abstract 4004.
  • [33] Lee M, Ryoo BY, Hsu CH, et al. Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). ESMO meeting 2019, Abstract LBA 39.
  • [34] Xu J, Shen L, Zhou Z, et al. Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep). ESMO meeting 2019, Abstract LBA 76.
  • [35] von Mehren M, Serrano C, Bauer S, et al. INVICTUS : A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ripretinib as ≥4th Line Therapy In Patients with AdvanCed Gastrointestinal Stromal TUmorS (GIST) Who Have Received Treatment with Prior Anticancer Therapies. ESMO meeting 2019, Abstract LBA 87.